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Abstract: Cystic fibrosis (CF) is mainly caused by the deletion of Phe 508 (∆F508) in the cystic fibrosis
transmembrane conductance regulator (CFTR) protein that is thus withheld in the endoplasmic
reticulum and rapidly degraded by the ubiquitin/proteasome system. New drugs able to
rescue ∆F508-CFTR trafficking are eagerly awaited. An integrated bioinformatics and surface
plasmon resonance (SPR) approach was here applied to investigate the rescue mechanism(s) of
a series of CFTR-ligands including VX809, VX770 and some aminoarylthiazole derivatives (AAT).
Computational studies tentatively identified a large binding pocket in the ∆F508-CFTR nucleotide
binding domain-1 (NBD1) and predicted all the tested compounds to bind to three sub-regions of
this main pocket. Noticeably, the known CFTR chaperone keratin-8 (K8) seems to interact with some
residues located in one of these sub-pockets, potentially interfering with the binding of some ligands.
SPR results corroborated all these computational findings. Moreover, for all the considered ligands,
a statistically significant correlation was determined between their binding capability to ∆F508-NBD1
measured by SPR and the pockets availability measured by computational studies. Taken together,
these results demonstrate a strong agreement between the in silico prediction and the SPR-generated
binding data, suggesting a path to speed up the identification of new drugs for the treatment of
cystic fibrosis.
Keywords: cystic fibrosis; computational chemistry; molecular dynamics; molecular modeling;
surface plasmon resonance
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1. Introduction
Cystic Fibrosis (CF) is the most common lethal monogenic disorder in Caucasians. It is due to
different mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a protein
composed of five domains: two nucleotide binding domains (NBD1 and 2), two transmembrane
domains (MSD1 and 2) and one regulatory domain (R) [1]. The mutations causing CF are classified
in five groups, according to the mechanism of CFTR loss-of-function [2]. The most common one,
occurring in 70–90% of CF patients, is the deletion of phenylalanine 508 (∆F508) in NBD1 that causes
inappropriate folding and structural instability of ∆F508-CFTR that, for this reasons, remains trapped
in the endoplasmic reticulum and is rapidly degraded by the ubiquitin/proteasome system.
Several molecular chaperones and co-chaperones, among which Hsp70/Hsc70, Hsp90, CHIP and
BAG-2 [3] are involved in CFTR intracellular processing. In particular, keratin 8 (K8) plays an important
role in ∆F508-CTFR retention and degradation, through a preferential binding to ∆F508-CTFR NBD1
with respect to its wild type (WT) counterpart. Accordingly, the inhibition of ∆F508-CFTR/K8
interaction leads to the rescue of the defective ∆F508-CFTR processing [4,5]. However, also if the
mutant protein is targeted to the plasma membrane through rescue maneuvers, the probability that
its channel is open is reduced. The deficit of CFTR at the plasma membrane has a major impact on
the respiratory system, since CF patients produce a thick mucus that cannot be cleared, resulting
in an impairment of innate defense against bacteria [6]. The resulting pulmonary infections cause
a progressive loss of respiratory function that, in the last stages of the disease, may require lung
transplantation as a life-saving intervention [7,8].
Current therapies are mostly aimed at treating CF symptomatically, e.g., by aggressive antibiotic
strategies for the clinical management of bacterial lung infections. Although these therapies has
significantly pushed forward the mean survival age of patients from early childhood in the 1950s to
the late 30s at present [9], the burden of CF care remains very high and life quality and expectancy for
most CF patients are still limited.
An ambitious therapeutic alternative is to address CF systemically, by means of small molecules
that restore the trafficking (correctors) and gating (potentiators) capacity of mutated CFTR. At this
regard, a big effort has been made in the last ten years to determine the complete human CFTR 3D
structure by means of homology modelling, NMR and X-rays studies. In addition, computational
studies and cell- or tissue-based assays have been used to elucidate the mechanisms of action of CFTR
drugs, in particular VX809 [10–15].
In this context, the mutated CFTR protein and its NBD1 domain represent ideal targets for small
molecules with rescuing activity on ∆F508-CFTR [10,16]. Leveraging high-throughput screening by
companies and academic labs, this approach has already lead to some interesting compounds that
however remain in need of better elucidation of their molecular mechanism of action. To this lack
of knowledge surely contributes the fact that up to now, the available experimental structures of
human WT or mutated NBD1 and complete CFTR are largely incomplete: as concerns NBD1, the
human protein lacks some regions and/or contains solubilizing mutations (reviewed by Lewis and
co-workers [17]). As for the recently released human CFTR model, its experimental structure presents
unsolved portions [14], so that a detailed picture of the conformational changes which result in channel
opening/closing remain to be fully resolved [18].
To clarify these points, possibly allowing a rational design and full characterization of potential CF
drugs, here we exploited a synergistic approach including high performance computational studies of
the murine NBD1 protein (available as complete WT and ∆508F mutated structures) and biomolecular
interaction analysis by surface plasmon resonance (SPR) for an accurate validation of the in silico
predictions. The former allows the full evaluation of the dynamic behavior(s) of proteins, simulating
real biological events such as the molecular interactions between a ligand and its target and the
conformational changes of CFTR variants in respect to the WT protein. The latter represents the golden
standard label-free technology for real-time analysis of molecular interactions also in the field of CF
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drug discovery [8,19], being able to generate high-quality data on affinity, kinetic and mechanistic
aspects of interactions occurring between target proteins and drug candidates [20,21].
To solidly validate the complementary approach made up by computational and SPR studies,
here we have investigated the interaction of three well characterized and promising CF correctors and
four new potentially interesting compounds (Figure 1) [22–26] and characterized their ability to bind
to ∆F508-NBD1.
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Figure 1. Structures of ligand dataset.
The results obtained by the computational approach resulted in agreement with SPR findings,
providing a detailed characterization of the ligand-protein interaction useful for an efficient screening
of large compo nd libraries, a better rational design and a tailored synthesis of new lead compounds
for the rescue of mutated CFTR.
2. Results
2.1. Characterization of the ∆F508-NBD1 Flexibility by Molecular Dynamics Simulations (MDS)
Several studies demonstrated that the ∆F508-NBD1 apo is thermodynamically and kinetically
destabilize at physiological temperature in respect to the WT NBD1 apo [27–29]. In order to highlight
which differences in structure and backbone flexibility were induced in the protein by the mutation, we
firstly focused our attention on exhaustive MDS studies of 200 ns on both WT NBD1 and ∆F508-NBD1
forms. In agreement with literature data [30,31] a very high flexibility was observed for ∆F508-NBD1
in comparison to the WT NBD1, that was not limited to the close environment of the ∆F508 residue
(Figure 2A).
To compare the flexibility of ∆F508 and WT NBD1, we computed the root mean square fluctuation
(RMSF), an average measure of atomic mobility of backbone atoms along the MDS. Results show very
high flexibility (Figure 2A) in five loops contained in a large region that forms the binding pocket
(predicted by CASTp program) and that includes residues from a highly conserved regions in all
NDB proteins, such as the Walker B motif, the signature sequence LSGGQ, the Q- and the H-loops
(Figure 2B) [32].
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highlighted in magenta and numbered from one to six. The three binding sub-pockets predicted for 
the data-set ligands are also indicated as colored circles: yellow, binding sub-pocket 1 (BSP1), the 
putative binding site for VX809; magenta, BSP2, the putative binding site for compound 5; light green, 
BSP3, the putative binding site for compounds 4 and 6. The grey arrow indicates the location of the 
ΔF508 mutated residue. 
2.2. Binding Sites Prediction 
It is expected that conformational changes within NBD1 impact its molecular interaction with 
small molecules. Thus, cluster analysis was exploited to select from MDS trajectory the most 
representative ΔF508-NBD1 conformation. Three clusters were obtained (with 51.5%, 25.6% and 9.1% 
of frames grouped with a distance <2 Å). From the most populated one we extracted the most 
representative conformation that was then used to perform docking analysis with the ligands (Figure 3) 
using both blind and local approaches. As a result, a putative binding site and binding mode could 
be rationally inferred for each ligand. For aminoarylthiazole (AAT) derivatives, equi-populated 
clusters of solutions with similar energy and inverse orientation of the ligand were observed in each 
run (Supplementary Materials, Table S1, Figures S1–S3). 
Figure 2. (A) oot ean square fluctuation (RMSF) of ∆F508-NBD1 protein. RMSF values for
∆F508 and WT NBD1 are reported in red and black respectively. Magenta bold dashes indicate
the regions composing the main binding pocket, numbered from one to six; (B) Ribbon representation
of the ∆F508-NBD1 protein. The regions forming the main binding pocket predicted by CASTp are
highlighted in magenta and numbered from one to six. The three binding sub-pockets predicted for the
data-set ligands are also indicated as colored circles: yellow, binding sub-pocket 1 (BSP1), the putative
binding site for VX809; magenta, BSP2, the putative binding site for compound 5; light green, BSP3,
the putative binding site for compounds 4 and 6. The grey arrow indicates the location of the ∆F508
mutated residue.
2.2. Binding Sites Prediction
It is expected that conformational changes within NBD1 impact its molecular interaction with
small molecules. Thus, cluster analysis was exploited to select from MDS trajectory the most
representative ∆F508-NBD1 conformation. Three clusters were obtained ( ith 51.5%, 25.6% and
9.1% of frames gr uped with a dist nce <2 Å). From the m st populated one we extracted the most
representative conformation that w s then used to perform docking a alysis with the li ands (Fig re 3)
using both blind and local approaches. As a esult, a putative binding site and binding mode could be
rationally inferred for eac ligand. For ami oarylthiazol (AAT) derivatives, equi-populated clusters
of solutions with similar energy and inverse orientation of the ligand were observed in each run
(Supplementary Materials, Table S1, Figures S1–S3).
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anchored to ΔF508-NBD1 via the same interactions all along the trajectory (Figure 4). 
 
Figure 4. Analysis of putative binding mode stability. RMSD along simulation time for the ΔF508-
NBD1/ligand complexes calculated with respect to the most representative conformation of the 
ΔF508-NBD1/ligand trajectory obtained from cluster analysis. The ligand and the ΔF508-NBD1 RMSD 
are depicted in red and in black, respectively. (A) VX809; (B) ligand 4; (C) ligand 5; (D) ligand 6. 
Figure 3. Workflow of the co putational approach a lie for bin ing site re iction an o ti ization.
Additional MDS were performed for each complex obtained from the docking calculations to
optimize the orientation and pose of the ligand in the binding site and to highlight the ligand’s moieties
involved in its interaction with the NBD1 domain. In addition, the values of root mean square deviation
(RMSD) between the starting and the terminal positions during MD simulations were calculated for
each ligand to evaluate its stability inside the BSP. VX809 and the two AAT derivatives 4 and 6 retain
their initial position consistently during MDS, thus remaining steadily anchored to ∆F508-NBD1 via
the same interactions all along the trajectory (Figure 4).
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A highly unstable binding was instead observed during the simulation for AAT derivative 5
(Figure 4C and further investigated below), for the inactive AAT derivative 7 (included in the study to
test the validity of the experimental protocol), for corrector 4a, (C4a) [11] and for VX770 (included in
the study since they have been proposed to act by a mechanism of action independent from the NBD1
module) (data not shown). Accordingly, SPR analysis demonstrated that C4a and VX770 actually do
not bind to ∆F508-NBD1 (Table 1).
Table 1. Affinity values (Kd) of the interactions of CF putative drugs with ∆F508-NBD1 calculated by
SPR analysis. Kd values were derived by Scatchard’s plot analysis of the equilibrium binding data.





VX809/∆F508-NBD1 24.2 ± 6.2
4/∆F508-NBD1 99.3 ± 14.5
5/∆F508-NBD1 40.3 ± 2.5
6/∆F508-NBD1 197.9 ± 4.5
7/∆F508-NBD1 n.d.
The binding instability of compound 5 observed during MDS (Figure 4C) was further investigated
in order to predict the protein conformation able to give a stable ligand-protein complex. Analysis of
the RMSD fluctuations as a function of time for the complex showed instability reflecting an unfolding
of the C/N terminal of the helix 9 X-ray structure.
A broader conformational freedom of ∆F508-NBD1 apo in respect to that of the WT NBD1 apo
was observed, mainly due to the reorganization of the interactions network between residues and
causing the exposure of a wider hydrophobic region [31]. On this basis, we searched for the best
∆F508-NBD1 conformation able to bind compound 5 in a stable way: by performing a hydrophobic
surface analysis considering 1000 equidistant frames along the MDS of the ∆F508-NBD1 apo (one each
200 ps), we observed that the hydrophobic exposed surface spanned from 45 to 53 Å2 (Figure 5A).
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The frame with the most hydrophobic exposed surface was then taken in consideration as the 
potential protein conformation able to stably bind compound 5 and used to repeat docking studies 
(Figure 3, right side). In this way, a new binding site could be predicted where the ligand locates with 
Figure 5. (A) Fluctuation of the hydrophobic surface area of ∆F508-NBD1 calculated considering
1000 equidistant structures along its dynamics (one each 200 ps). The frame number 462 with the most
exposed hydrophobic surface used for compound 5 docking studies and 53.56, the value corresponding
to its hydrophobic surface in Å2, are indicated in red; (B) RMSD of atomic loci along the MDS trajectory
of the ∆F508-NBD1/compound 5 complex calculated in respect to the frame number 462 and plotted
against simulation time. Black and red lines refer to ∆F508-NBD1 backbone and ligands, respectively.
All structure indices in x-axis must be multiplied by 1000 to obtain the frame index.
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The frame with the most hydrophobic exposed surface was then taken in consideration as the
potential protein conformation able to stably bind compound 5 and used to repeat docking studies
(Figure 3, right side). In this way, a new binding site could be predicted where the ligand locates
with high stability, at variance with what observed for the binding site previously predicted with the
docking simulations based on the most representative conformation of ∆F508-NBD1 apo (Figure 4C).
2.3. Ligand Interactions on ∆F508-NBD1
Ligand interactions information obtained from MDS predicted that the most effective ligand
VX809 is anchored in the BSP1 region of ∆F508-NBD1 by three H-bonds, the first between its amidic
nitrogen and Y577, the second between its carbonyl group and E655 and the third between one of its
catechol oxygens and V580 (Figure 6A and Supplementary Materials, Figures S4 and S6).
Molecules 2018, 23, 120 7 of 19 
 
high stability, at variance with what observed for the binding site previously predicted with the 
docking simulations based on the most representative conformation of ΔF508-NBD1 apo (Figure 4C). 
2.3. Ligand Interactions on ΔF508-NBD1 
Ligand interactions information obtained from MDS predicted that the most effective ligand 
VX809 is anchored in the BSP1 region of ΔF508-NBD1 by three H-bonds, the first between its amidic 
nitrogen and Y577, the second between its carbonyl group and E655 and the third between one of its 
catechol oxygens and V580 (Figure 6A and Supplementary Materials, Figures S4 and S6). 
 
Figure 6. Predicted binding mode of VX809 (A) and compound 5 (B) with ΔF508-NBD1. The residues 
involved in the H-bonds between the ligands and the mutated protein are shown as sticks in red dotted 
line. The protein is shown as ribbon. Conserved NBD signature sequences are shown as red ribbon. 
Binding of compound 5 seems to occur in another NBD1 sub-pocket (BSP2) via a network of  
H-bonds: one between the sulphur atom of the AAT ring and R555, a very important residue of the 
RXR motif [33], another between the hydrogen of the aminic nitrogen of compound 5 and T582. Also, 
a π-π interaction between the thiazolic ring of the AAT and Y577 seems to occur that further stabilizes 
the interaction (Figure 6B and Supplementary Materials, Figure S6). 
Compounds 4 and 6 seem to bind to a further different sub-pocket (BSP3). Compound 4 making 
two H-bonds between the sulphur atom of its thiazole ring and R553 and between its amidic nitrogen 
and N416 (Figure 7A and Supplementary Materials Figure S5). Concerning the compound 6/ΔF508-
NBD1 interaction, cluster analysis on MDS trajectory predicted three equipopulated clusters with a 
17% of occurrence each. This result is different from the other complexes analyzed, where occurrences 
of the most representative cluster are 46%, 38% and 33% for VX809, compound 4 and compound 5, 
respectively. In all the clusters, a H-bond between compound 6 and S495 (a residue located in the  
Q-loop) can be predicted, while only in one cluster a transient H-bond between compound 6 and 
R555 seems to occur, due to alternative orientations of the side chain of the residue during the 
dynamics. Thus, at variance with VX809, all the other compounds studied seem to bind ΔF508-NBD1 
via residues belonging to the conserved NBD signature sequences, further supporting the hypothesis 
of different binding modes of the ligands to NBD1. Important to note, the binding modes here 
proposed for VX809 do not fully agree with some literature results proposing binding poses at the 
ICL4:NBD1 inter-domain interface and along strand S9 and strand S10 [10–13,15]. It must be pointed 
out however that all these studies were performed on RI-del human NBD1, without performing MDS 
to evaluate the stability complex. 
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involved in the H-bonds between the ligands and the mutated protein are shown as sticks in red dotted
line. The protein is shown as ribbon. Conserved NBD signature sequences are shown as red ribbon.
Bi ding of compound 5 seems occur in another NBD1 sub-pocket (BSP2) via a network of
H-bonds: one between th sulphur atom of the AAT ring a d R555, a very import t residue of the
RXR motif [33], another between the hydrogen of the minic nitrogen f compound 5 and T582. Also,
a π-π interaction between the thiazolic ring of the AAT and Y577 seems to occur that further stabilizes
the interaction (Figure 6B and Supplementary Materials, Figure S6).
Compounds 4 and 6 seem to bind to a further different sub-pocket (BSP3). Compound 4
making two H-bonds between the sulphur atom of its thiazole ring and R553 and between its
amidic nitrogen and N416 (Figure 7A and Supplementary Materials, Figure S5). Concerning
the compound 6/∆F508-NBD1 interaction, cluster analysis on MDS trajectory predicted three
equipopulated clusters with a 17% of occurrence each. This result is different from the other complexes
analyzed, where occurrences of the most representative cluster are 46%, 38% and 33% for VX809,
compound 4 and compound 5, respectively. In all the clusters, a H-bond between compound 6 and
S495 (a residue located in the Q-loop) can be predicted, while only in one cluster a transient H-bond
between compound 6 and R555 seems to occur, due to alternative orientations of the side chain of
the residue during the dynamics. Thus, at variance with VX809, all the other compounds studied
seem to bind ∆F508-NBD1 via residues belonging to the conserved NBD signature sequences, further
supporting the hyp thesis of differe t binding mo es of the ligands to NBD1. Important to note, the
binding modes here propose for VX809 do not fully agree with some literat re results proposing
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binding poses at the ICL4:NBD1 inter-domain interface and along strand S9 and strand S10 [10–13,15].
It must be pointed out however that all these studies were performed on RI-del human NBD1, without
performing MDS to evaluate the stability complex.Molecules 2018, 23, 120 8 of 19 
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Some CFTR-targeted drugs exert their action by impairing the binding of ∆F508-NBD1 to K8,
thus escaping the ubiquitin-proteasome machinery. This observation, together with the different
positioning of the various AAT derivatives in the NBD1 module, prompted us to evaluate the capacity
of the various compounds studied to interfere with the K8/∆F508-NBD1 interaction. As a result, the
binding pockets of VX809 and 5, as determined by MDS and docking (BSP1 and BSP2, respectively),
turned out to be distinct from the binding site of K8 already reported by Odolczyk [34]. The binding
modes of compounds 4 and 6 indicated instead that they share part of their binding pocket with the K8
anchoring cleft. In details, the aromatic ring of compound 4 bringing the methylsulphur moiety seems
to be partially inserted into the anchoring cleft of K8 (Figure 7A), while the 2-oxazolidinone moiety of
compound 6 appears to be completely inserted into an inner portion of the K8 anchoring cleft, with
the remaining part of the molecule situated in the adjacent sub-pocket, making two H-bonds between
its aminic nitrogen and G756 and between the sulphur atom of its methylsulphur moiety and E656
(Figure 7B and Supplementary Materials, Figure S7).
2.4. Interaction Analysis by Surface Plasmon Resonance
SPR analyses were finally performed to validate the in silico predictions that, as already stated
above, is the main aim of this work. In a first series of experiments, to check the correct immobilization
and binding availability of ∆F508-NBD1 onto the sensor chip, we performed binding analyses with
K8 in those same experimental conditions used to analyze the binding of the putative CF drugs
(see Materials and Methods). As shown in Figure 9A, when tested at 600 nM, K8 specifically binds to
immobilized ∆F508-NBD1 but not to BSA surface (here used as a negative control). When increasing
concentrations of K8 were injected onto the ∆F508-NBD1 surface, the blank subtracted sensorgrams
overlay shown in Figure 9B was obtained: K8/∆F508-NBD1 interaction occurs in a saturable and very
stable way, being K8 detachment from the sensor chip after the end of the injection very slow.
Once validated the experimental model, the direct interaction of the putative CF drugs with
∆F508-NBD1 was investigated. In agreement with computational predictions, VX770, C4a and
compound 7 do not bind to ∆F508-NBD1 (Table 1). The other compounds bind to ∆F508-NBD1
but, at variance with K8, their interaction is characterized by a very quick detachment from the sensor
chip after the end of the injection (Figure 9A–D). For compounds 4 and 5 in particular, their premature
detachment from surface-immobilized ∆F508-NBD1 can be appreciated even during the association
phase, causing an anomalous shaped sensorgram. This may be explained by the limited solubility
of small chemical compounds and their tendency to aggregate during the SPR analysis also in the
presence of DMSO [36].
Blank subtracted values of RU bound at equilibrium obtained from injections of increasing
concentrations of the various putative CF drugs on ∆F508-NBD1 were then used to build the curves
reported in Figure 9E–H: VX809, compounds 5 and 4 bind to ∆F508-NBD1 in a dose-dependent and
saturable manner, with Kd values ranging between 24.2 ± 6.2 and 99.3 ± 14.5 µM. At the concentrations
tested, compound 6 shows no saturable binding, with a presumed Kd value equal to 197.9 ± 4.5 µM
(Table 1).
In silico studies predicted VX809 and compound 5 to locate in two distinct regions of ∆F508-NBD1
(BSP1 and 2, respectively) and compounds 4 and 6 to locate in region BSP3 proposed to be also involved
in the binding to K8 [37]. These observations prompted us to evaluate the capacity of the various
compounds to affect the binding of K8 to ∆F508-NBD1. In a first series of experiments, exploiting the
slow dissociation rate of the K8/∆F508-NBD1 interaction, a saturating amount of the chaperone was
injected over the ∆F508-NBD1 surface and allowed to reach an equilibrium binding. Subsequently, the
putative drugs were injected.
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Figure 9. SPR analysis of the interaction of ∆F508-NBD1 with K8 or with the putative CF drugs.
(A) Sensorgrams showing the binding of K8 (600 nM) to a ∆F508-NBD1- or to a control BSA-coated
surface; (B) Blank-subtracted sensorgrams overlay showing the binding of increasing concentrations
of K8 (1000, 600, 300, 150, 75, 37.5 nM) to the ∆F508-NBD1-coated sensor chip; (C–F) Representative
blank-subtracted sensorgrams overlays showing the binding of increasing concentrations of the
indicated compounds to the ∆F508-NBD1-coated sensor chip. In all the panels, response (in RU)
was recorded as a function of time. White and black arrows mark the beginning and the end of the
injection of K8 or of the compounds; (G–L) Steady-state analysis obtained by fitting the proper form
of Scatchard’s equation for the plot of the bound RU at equilibrium versus the ligand concentration
in solution for the indicated compounds injected onto the sensor chip-immobilized ∆F508-NBD1.
Red lines indicate the calculated (G,H) or presumed (L) Kd values.
As shown in Figure 10A, injection of VX809 or of compound 5 on the K8-saturated ∆F508-NBD1
surface results in an increase of bound RU, indicating that these two compounds retain the capacity to
bind to ∆F508-NBD1 also when the protein is already engaged by K8. Relevant to this interpretation,
none of the compounds studied is able to bind to K8 (Figure 10B). The inability of compounds 4 and 6
to alter the binding of K8 to ∆F508-NBD1 (Figure 10A) may be due to the fact that the ∆F508-NBD1/K8
interaction is too stable to be disrupted by the subsequent injection of the two compounds that indeed
turned out to be the two weakest ∆F508-NBD1 binders (Table 1). In any case, the capacity of both the
AATs and K8 to bind to immobilized ∆F508-NBD1 makes this experimental model inappropriate to
study possible competitive effects. To overcome this limit, we reversed the SPR model by immobilizing
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K8 and evaluating its capacity to bind ∆F508-NBD1 (injected at 600 nM) in the presence of the
compounds at a dose (500 µM) compatible with the highest concentration of DMSO (5%) that does
not hamper the K8/∆F508-NBD1 interaction (data not shown). As already mentioned, none of the
compounds interacts with immobilized K8 in these experimental conditions (Figure 10B). As shown
in Figure 10C, when injected alone, ∆F508-NBD1 binds to immobilized-K8 (35 RU at equilibrium).
The injection of ∆F508-NBD1 in the presence of VX809 or compound 5 results in an interaction that is
quantitatively higher (68 and 45 RU at equilibrium, respectively), confirming the results obtained in
the previous SPR assay. On the contrary, in the same experimental conditions, compound 4 exerts a
50% inhibition of the ∆F508-NBD1/K8 interaction, indicating that it competes with immobilized K8
for the binding to ∆F508-NBD1 while compound 6 resulted again ineffective, possibly because of its
extremely low affinity interaction with ∆F508-NBD1 (Table 1). In conclusion, also when dealing with
the effect of the drugs on ∆F508-NBD1/K8 interaction, computational predictions are validated by
experimental SPR analysis.Molecules 2018, 23, 120 11 of 19 
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Figure 10. Effect of the putative CF drugs on the K8/∆F508-NBD1 interaction. (A) Representative
sensorgrams showing the injection of the various compounds (at 150 µM) onto ∆F508-NBD1-coated
sensor chip saturated with K8. The black arrow marks the end of K8 injection. Light and dark grey
arrows mark instead the beginning and the end of the subsequent injection of the various compounds
on the K8-saturated surface; (B) Representative sensorgrams showing the injection of the various
compounds (500 µM) onto K8-coated sensor chip. White and black arrows mark the beginning and
the end of the injection of the compounds, respectively; (C) Representative sensorgrams showing the
injection of ∆F508-NBD1 (600 nM) onto K8-coated sensor chip in the absence or in the presence of
the indicated compounds (500 µM). White and black arrows mark the beginning and the end of the
injection of the various mixtures, respectively. In all the panels, the response (in RU) was recorded as a
function of time. The sensorgrams shown are representative of other two that gave similar results.
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A last relevant aspect is the statistically significant correlation that exists, for each compound,
between the values of maximal RU bound to sensor chip-immobilized ∆F508-NBD1 at equilibrium
and the different time availability of the ∆F508-NBD1 pockets as calculated from the docking poses
simulation along the MD of the protein in apo form (Supplementary Materials, Figure S4). VX809
binds to the highest number of available ∆F508-NBD1 conformations (48%) and, accordingly, it shows
also the highest binding capacity when tested in SPR (Supplementary Materials, Table S2). The
AAT derivatives behave differently, with compounds 5 and 4 able to bind only 15% of the available
conformations and compound 6 showing an intermediate capacity (22%).
Again, these values quantitatively correlate to the values of maximal RU bound at equilibrium
(Supplementary Materials, Table S2). The disclosed correlation between these latter values and the
different time availability of the ∆F508-NBD1 pockets suggests that ∆F508-NBD1 retains its capacity to
present different conformations also when immobilized to the sensor chip. As a result, the different
time availability of its distinct binding pockets reflects in a different binding capacity that could be
not directly related to the measured binding affinity. The take-home message is that both pocket
availability (as predicted by computational studies) and the values of maximal binding at equilibrium
(as calculated by SPR analysis) should be taken into account when evaluating the efficacy of a potential
lead compound, further underlying the validity of the double approach here proposed.
3. Discussion
In this work, by means of extensive MDS simulation and docking, we have studied the interaction
of ∆F508-NBD1 with a series of AAT derivatives and VX809, selected as template. The results of
these studies allowed the prediction of putative binding modes with statistics of occurrence that
finally turned out to be in agreement with actual SPR binding analysis, linking solidly these two
complementary techniques. This in-tandem approach, here applied to the murine NBD1 domain, can
contribute to unravel the complex puzzle concerning the mechanism of action of small molecules
in CFTR-targeted therapy, an issue that is commonly acknowledged as not fully understood, due
mainly to the still present limits of the experimental structures of human NBD1 and complete CFTR
(see Introduction).
The computational investigations on ∆F508-NBD1 here performed provided novel insights
regarding the binding mode of known and novel potential CF drugs: the well-known VX809 was
predicted to strongly anchor to the central cleft of NBD1 via three H-bonds. Accordingly, when
compared to the ATT derivatives in SPR analysis, it shows the highest binding affinity for ∆F508-NBD1
(Table 1). In respect to VX809, the three AAT derivatives 4, 5 and 6 seem not to share the same
binding site, even if endowed of the same chemical scaffold. In details, compound 6 appears
to occupy a sub-region inside the main pocket, orienting its carbonyl group towards S495 in the
Q-loop. Compound 4 presents a slightly different predicted binding since in its scaffold is present
a p-bromophenyl moiety that is less polar than compound 6 and whose carbonyl group causes the
molecule to accommodate in the same sub-pocket but in a different mode, flanking the RXR motif.
Interestingly, modelling and mutagenesis studies on NBD1/NBD2 dimers showed that activator
compounds strongly interact with the NBD1 domain in a site that includes part of the Q-loop, of the
LSGGQ signature, of switch-II of NBD1 plus the Q-loop of NBD2 [38]. These computational findings
support the evidence that compound 6 acts as a potentiator [26]. Furthermore, NMR spectra of various
NBD1 mutants support the evidence that deletion of Phe-508 affects Q-loop conformation inhibiting
dimerization, possibly explaining the mechanism by which the mutation impairs the opening of the
channel [38] and rationally supporting the selection of ∆F508-NBD1 as the primary target for designing
new activators.
Compound 5 is predicted to bind to BSP2 inside the main pocket, closer to the LSSGQ conserved
residues and specifically interacting with R555 of the RXR motif, a conserved portion of NBD1 already
reported to be important for CFTR correct folding and stability [39]. Thus, a possible mechanism of
action of compound 5 can be its capacity to prevent the abnormal accessibility of RXR in ∆F508-NBD1,
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thus preventing mistrafficking of the mutated protein. Also, the predicted different binding modes
of compound 5 and VX809 are in agreement with the observation that the two compounds show a
synergistic effect in vitro [26].
The predicted distinct binding modes of the AAT derivatives correlate to their different scaffold
decorations and support their double biological activity [23]. In fact, according to our calculations, the
interaction of compound 6 with S495 residue in the Q-loop may promote the dimerization of NBD1
with NBD2 and thus the following channel opening (potentiator activity). On the other hand, the
predicted H-bonds of compounds 5 and 4 with the arginine residues of the RXR motif may alter the
interaction between ∆F508-NBD1 and the proteostasis components (CFTR interactome) allowing the
protein to reach the plasma membrane (corrector activity).
Finally, it is interesting to note that the binding modes we have inferred by MDS and docking
suggest that compounds 4 and 6, but not VX809 and compound 5, partially insert in the proposed K8
binding site of ∆F508-NBD1, each one in a specific way.
These predicted binding modes were validated by SPR analysis that showed that compound 4
displaces K8 from its binding to ∆F508-NBD1, while VX809 and compound 5 can bind the protein
simultaneously to K8. This also suggests the possibility that the well demonstrated rescuing capacity
of VX809 in vivo [23,26] is K8-independent, being possibly mediated though the disruption of the
interaction of ∆F508-NBD1 with chaperone(s) other than K8. This calls for further studies aimed
at evaluating the effect of VX809 (as well as of other compounds) on chaperones different from K8
(i.e., Hsp70/Hsc70, Hsp90, CHIP and BAG-2) [3]. On the other hand, in silico predictions and SPR
analysis point to compound 4 as a very interesting lead compound being able to displace 50% of
K8 in its binding to ∆F508-NBD1. In effect, as already reported by Colas et al. [4], the disruption of
K8/∆F508-NBD1 interaction leads to the functional correction of the mutated protein. Further studies
are required to fully clarify these points since the specific residues of ∆F508-NBD1 that directly interact
with K8 (as well as with other chaperones) still need to be experimentally defined.
In conclusion, the in-tandem approach made up of in silico studies and SPR analysis points to
different binding modes (and different binding affinity) for VX809 and the various AATs that, in
turn, indicate two potential rescue mechanisms: the first consisting in the capacity of the compound
(i.e., VX809 and compound 5) to stabilize the conformational variability of NBD1, the second consisting
instead in the capacity of the compound (i.e., compound 4 and possibly compound 6) to interfere with
the binding of K8 to ∆F508-NBD1.
Finally, it is interesting to note that the SPR-generated values of RU bound at equilibrium to
∆F508-NBD1 and the docking poses of ∆F508-NBD1-ligand evaluated by inverse docking technique
(Supplementary Materials, Table S2) correlate in a statistically significant way (Supplementary
Materials, Figure S4), suggesting that the former parameter depends on the actual availability of the
binding pockets that are variably exposed during the structural fluctuation of ∆F508-NBD1. In turn, this
indicates that, once immobilized to a surface, the mutated protein maintains (at least in part) its capacity
to move in the space, assuming those different conformations assessed by computational analysis.
The results of this work open up to further researches with multiple purposes: (a) to validate
the putative binding modes of the compounds with ∆F508-NBD1 mutagenesis in those amino acids
predicted to be involved in the interactions; (b) to correlate the various disclosed binding modes to
different recovery effects of the compounds on ∆F508-CFTR by means of in vitro experiments; (c) to
study the effect of selected compounds on the interaction of ∆F508-NBD1 with chaperones other than
K8; (d) to speed up the design and synthesis of new and more efficient AAT derivatives, able to correct
the ∆F508-NBD1 defect; (e) to better understand the molecular mechanisms of interactions and action
of the new compounds, useful for a more exhaustive knowledge of CFTR disease.
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4. Materials and Methods
4.1. Computational Studies
4.1.1. Ligand Dataset
The ligand dataset has been chosen including three well known compounds provided by L.J.V.
Galietta and here used as references: VX809 (Lumacaftor, one of the most effective correctors [24]);
VX770 (Ivacaftor, a potentiator that does not bind to NBD1 [22] and that has been recently approved
for CF therapy by both FDA and EMEA); C4a that, as VX770, does not bind to NBD1 [11,25]. Four new
AAT derivatives, already synthesized by some of us, were also included: compounds 4, 5, 6 and the
inactive compound 7 [23,26] (Figure 1). All compounds were built, parameterized (Gasteiger-Hückel
method) and minimized with OMEGA 2.5.1.4: (OpenEye Scientific Software, Santa Fe, NM, USA,
www.eyesopen.com) using MMFF94 force field. Regarding VX809 (characterized by a carboxylic
moiety), accurate pKa predictions performed with ChemSpider (a free web tool from the Royal Society
of Chemistry that can be found at: http://www.chemspider.com) let us to reasonably suppose that it
maintains its anionic form at physiological pH, and calculations were performed accordingly.
4.1.2. Model Refinement
Since the WT and ∆F508-NBD1 proteins available for our SPR analysis were the murine forms
obtained from CFTR folding consortium (see below), we performed all computational studies using
the murine crystallographic structures.
WT- and ∆F508-NBD1 models (spanning residues 389–673) were based on the crystal structure of
NBD1 from mouse CFTR, 1R0Z [40] and 3SI7 [41]. The phosphorylation on residues Ser422, Ser659,
Ser660, and Ser670 were removed. Both structures presented an ATP-Mg2+ complex. The gap of
six residues spanning positions 414–419 present on the WT NBD1 was modelled ab initio with loop
refinement algorithm of Modeller [42], a tool relying on a scoring function and on an optimization
schedule suitable for loop modelling. In details, hundreds of loop models were generated and their
potential energy was evaluated with the DOPE scoring function. The lowest energy loop model was
then chosen and the resulting WT model was used as a template to bridge the gap in the mutant
domain (spanning residues 414–428).
4.1.3. MDS Simulations
MD simulations were carried out using Amber 12 Molecular Dynamics Package. The compounds
and the proteins were parameterized by means of the empirical charge model AM1-BCC (using the
Antechamber module) and of the AMBER99SB-ILDN force field, respectively. The NBD1 module
of CFTR was capped with an acetyl group on its N-terminus and with a N-methylamide on its
C-terminus. The complex was solvated in a truncated octahedron box (8 Å distance between protein
and box wall) using the explicit TIP3P water model. Na+ ions were added to neutralize the whole
system. Minimization of the system was performed by several stages of steepest descent and conjugate
gradient to remove bad contacts and release restraints.
Using NVT conditions the system was weakly coupled to a temperature bath of 300 K under
control with the Langevin algorithm that uses a simple Leapfrog integrator to propagate the dynamics.
Next, in NPT conditions, the Berendsen pressure coupling of 1 atm with a collision frequency of 2 ps−1
was applied. After equilibration, MDS trajectories were carried out for 200 ns with an integration
step of 2 fs. All the bonds involving hydrogen atoms were constrained by the SHAKE algorithm. The
non-bonded cut-off distance was set to 8 Å and long range electrostatic interactions were calculated
using Particle Mesh Ewald (PME) method.
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4.1.4. Docking Studies, Ligand-Protein Docking
The most representative conformations were obtained from the most populated cluster of the
∆F508-NBD1 MDS using the backbone atoms to compute the distance between each pair of frames
(Figure 3, left side). A sampling of 10,000 frames along the trajectory was used for cluster analysis.
This conformation was used to perform ligand-protein docking calculations. We checked that the
docking poses were correctly inside the docking binding sub-pockets in the putative binding pocket
predicted by CASTp [43]. Autodock Tools [44] was used to prepare proteins and ligands for the
docking computations and to analyze the results. Polar hydrogen atoms were added to proteins
and ligands and non-polar hydrogen atoms were merged. Finally, Gasteiger charges were added
to all atoms. Protein coordinates were set to be rigid while ligand bonds were set to be rotatable.
Blind (no specific binding pocket is searched) and local (docking targeting a specific binding pocket)
protocols were performed to predict the binding sites for each ligand of the dataset. In particular, in
blind docking calculations, a grid box encompassing the entire NBD1 structure was generated to take
in consideration all the possible NBD1 binding sites. Calculations were carried out using Auto-Dock
Vina [45]. The exhaustiveness of the global search was set to 64. The complex models with the lowest
energy (based on an evaluation of AutoDock Vina’s empirical scoring function) were selected.
A local docking set of experiments was performed to predict the binding of each ligand of the
dataset and to optimize the ligand-protein interactions. Both Autodock Vina and AutoDock4 were
used for local docking and finally only the latter was used due to ambiguities (same energy and
different pose) in the choice of the best pose in Autodock Vina results. AutoDock4 was used with a
grid box centered on the binding regions predicted in the blind docking calculations. The affinity maps
for all the atom types present, as well as an electrostatic map, were computed with a grid spacing
of 0.375 Å. The search was carried out with the Lamarckian Genetic Algorithm, with the number of
generations, energy evaluations and docking runs set to 27,000, 2,500,000, and 100 respectively [44].
Considering only the most populated clusters, we retained a set of two or three clusters with similar
energy and numerosity. For each cluster we selected the pose with the lowest energy and used the
corresponding complex to run an MD simulation for 200 ns using the PME method. In this way we
filtered out the dynamically unstable poses retaining only those that were stable.
This procedure allowed us to predict a stable docked pose for VX809, compounds 4 and 6 but not
for compound 5 for which we used another approach: hydrophobic surface analysis performed on
1000 frames along the MDS trajectory of ∆F508-NBD1 allowed the prediction of the frame with the
most exposed hydrophobic surface (Figure 3, right side). Thereafter, the procedure was identical to the
one described above (blind docking, MDS and stability analysis).
4.1.5. Docking Studies, Inverse Docking Technique to Calculate Binding Propensity
In order to try to explain the experimental RU values obtained by SPR analysis in relation to
the pocket availability at equilibrium of the ∆F508-NBD1, we used a ligand-protein inverse docking
technique to obtain a measure of how many ∆F508-NBD1 structural conformations along the MDS are
able to bound to their respective ligands (Figure 11).
We implemented a protein pocket dataset that includes the three pockets (BSP1, BSP2, BSP3)
obtained from the workflow illustrated in Figure 3, and performed docking analysis of each pocket
against a selection of 1000 time-equidistant frames along the MDS of the ∆F508-NBD1 (one each
200 ps). The computations were carried out using local docking with Auto-Dock Vina. For each
ligand/∆F508-NBD1 docking simulation, the lowest energy complex was identified and for each
ligand, all docked poses over the 1000 frames were grouped by similar ligand-pocket distance between
the docking pose and the reference pose, the latter obtained considering the most frequent cluster of
the dynamic of the complex. The results were then compared to the mean value of the binding energy
of the group, allowing the evaluation of the number of ∆F508-NBD1 conformations able to bind to
each compound (Table S2).
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4.1.6. Trajectory Analysis
MDS trajectories were analyse usi g the root mean square deviation (RMSD) and the root mean
square fluctuation (RMSF) techniques plus the hydrophobic surface (HS). RMSD was used as a measure
of the stabil ty of the unbound prot ins compared to the crystallographic structures and as measure
of the ligand complex along the dynamics compared to its starting pose ob in d from docking. RMSF
wa use to determi e the fluctuating egions in ∆F508-NBD1, highlighting the differ nces in flexibility
in respect to the WT form of th protein.
HS area was computed with the per-residue Shrake-Rupley method [46] us g 1200 probes with a
1.4 Å radius to evaluate the ∆F508-NBD1 hydrophobic exposure area during the simulations.
4.2. Reagents and Recombinant Proteins
urine WT NBD1 and ∆F508-NBD1 were obtained from CFTR Folding Consortium [37].
K8 was purchased by Pro-Spec-Tany TechnoGene Ltd. (Ness Ziona, Israel). The reagents
1-ethyl-3-(3-diaminopropyl)carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS)
were purchased from GE Healthcare (Milwaukee, WI, USA).
4.3. Surface Plasmon Resonance (SPR) Binding Assay
SPR measurements were performed on a BIAcore X-100 instrument (GE-Healthcare, Milwaukee,
WI, USA), using research-grade CM5 carboxyl-methyl-dextran–coated sensor chips (GE-Healthcare).
The murine ∆F508-NBD1 was resuspended at 20 µg/mL in 10 mM sodium acetate pH 4.0 and allowed
to react with the first flow cell of a CM5 sensor chip pre-activated with 50 µL of 0.2 M EDC and 0.05 M
NHS and deactivated by injection of HCl–ethanolamine. This procedure led to the immobilization of
11,000 RU, equal to approximately 400 fmol/mm2 of protein. Similar results were obtained for the
injection of BSA (20 µg/mL) onto the second flow cell of each sensor chip, used as a negative control
and for blank subtraction. The appropriate immobilization of ∆F508-NBD1 was checked by injecting
increasing concentrations of K8 in PBS, 0.05% surfactant P20 and 5% DMSO, pH 7.4 over the sensor
chip for 90 s at 10 µL/min, 25 ◦C and then washed until dissociation was observed. The inclusion
of 5% DMSO in the running buffer (not necessary for protein-protein interaction analysis) and the
short association time were chosen to validate ∆F508-NBD1 binding availability in the experimental
conditions used for the subsequent analysis of the compounds (see below).
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4.3.1. Direct Binding Analysis
For the evaluation of their capacity to directly bind to ∆F508-NBD1, increasing concentrations of
the various compounds of the data-set were resuspended in PBS, 0.05% surfactant P20 and 5% DMSO,
pH 7.4, injected over ∆F508-NBD1 or BSA surfaces for 90 s at 10 µL/min, 25 ◦C and then washed
until dissociation was observed. Steady state analysis were performed by fitting the proper form of
Scatchard’s equation for the plot of the bound RU at equilibrium versus the compound concentration
in solution. When saturation binding was reached, Kd values were calculated. In the case no saturation
could be reached due the limited solubility of the compound under test, the software provided a Kd
value expected on the bases of the curve’s trend.
In a further series of experiments, a saturating amount of K8 (1 µM) was injected on the
∆F508-NBD1 surface and allowed to reach an equilibrium binding. Then, the various compounds of the
data-set (150 µM) were injected and their capacity to affect the binding of K8 to ∆F508-NBD1 evaluated.
4.3.2. Competition Assays
K8 was used since, as a representative ∆F508-CFTR chaperones, has been repeatedly used
for SPR studies [4,34,47] and its binding site in ∆F508-CFTR has been mapped [34]. To perform
competition assays for the binding to ∆F508-NBD1 between the various compounds and K8, the
latter was resuspended at 20 µg/mL in 10 mM sodium acetate pH 4.0 and allowed to react with the
first flow cell of a CM5 sensor chip pre-activated with 50 µL of 0.2 M EDC and 0.05 M NHS and
deactivated by injection of HCl–ethanolamine. This procedure led to the immobilization of 7800 RU of
the protein, (equal to approximately 146 fmol/mm2). Similar results were obtained for the injection of
BSA (10 µg/mL) onto the second flow cell of each sensor chip, that was then used as a negative control
and for blank subtraction. ∆F508-NBD1 (at 600 nM) in the absence or in the presence of the various
compounds (all at 500 µM) in 0.05% surfactant P20 and 5% DMSO, pH 7.4, was injected over the K8 or
BSA surfaces for 90 s at 10 µL/min, 25 ◦C and then washed until dissociation was observed.
Supplementary Materials: Supplementary materials are available online.
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